Gilead Sciences (GILD) : 8 brokerage houses believe that Gilead Sciences (GILD) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 9 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Gilead Sciences (GILD). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 18 Wall Street Analysts endorse the stock as a Buy with a rating of 2.06.
Gilead Sciences (GILD) : The most positive equity analysts on Gilead Sciences (GILD) expects the shares to touch $125, whereas, the least positive believes that the stock will trade at $93 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $109.5 with an expected fluctuation of $9.55 from the mean.
Shares of Gilead Sciences Inc. appreciated by 2.8% during the last five trading days but lost 8% on a 4-week basis. Gilead Sciences Inc. has dropped 4.98% during the last 3-month period . Year-to-Date the stock performance stands at -18.64%. Gilead Sciences (NASDAQ:GILD): stock turned positive on Tuesday. Though the stock opened at $81.46, the bulls momentum made the stock top out at $81.64 level for the day. The stock recorded a low of $81.02 and closed the trading day at $81.47, in the green by 0.68%. The total traded volume for the day was 8,279,418. The stock had closed at $80.92 in the previous days trading.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.